Cargando…

Pilot Equivalence Study Comparing Different Batches of Topical 0.025% Capsaicin Emulsion: Product Microstructure, Release, and Permeation Evaluation

The European Medical Agency (EMA) has issued a draft guideline on the quality and equivalence of topical products. The equivalence for complex semisolid formulations involves several steps: the same quantitative content, the same microstructure, the same release, and permeation profile. In this pape...

Descripción completa

Detalles Bibliográficos
Autores principales: Navarro-Pujol, Francesc, Bulut, Sanja, Hessman, Charlotte, Karabelas, Kostas, Nieto, Carles, Fernandez-Campos, Francisco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705898/
https://www.ncbi.nlm.nih.gov/pubmed/34959364
http://dx.doi.org/10.3390/pharmaceutics13122083
_version_ 1784622060272615424
author Navarro-Pujol, Francesc
Bulut, Sanja
Hessman, Charlotte
Karabelas, Kostas
Nieto, Carles
Fernandez-Campos, Francisco
author_facet Navarro-Pujol, Francesc
Bulut, Sanja
Hessman, Charlotte
Karabelas, Kostas
Nieto, Carles
Fernandez-Campos, Francisco
author_sort Navarro-Pujol, Francesc
collection PubMed
description The European Medical Agency (EMA) has issued a draft guideline on the quality and equivalence of topical products. The equivalence for complex semisolid formulations involves several steps: the same quantitative content, the same microstructure, the same release, and permeation profile. In this paper, several batches of a low strength topical product, which we used as a reference/comparator product, were evaluated according to the recommendations of the EMA draft guideline. The batches were 0.025% capsaicin emulsions from the same manufacturer that were evaluated in terms of droplet size, X-ray diffraction patterns, rheology, release, and permeation profile. The generated data revealed a large batch-to-batch variability, and if the EMA guideline was applied, these batches would not be considered equivalent, although they were produced by the same manufacturer. The result of this work illustrates the difficulties in obtaining equivalence according to the current draft guidelines. It also highlights that the equivalence guidelines should consider the variability of the comparator product, and in our opinion, the guidelines should allow for claiming equivalence by comparing the limits in the variability of the data generated for the comparator product with the limits in the variability of the data generated for the intended equivalence product.
format Online
Article
Text
id pubmed-8705898
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87058982021-12-25 Pilot Equivalence Study Comparing Different Batches of Topical 0.025% Capsaicin Emulsion: Product Microstructure, Release, and Permeation Evaluation Navarro-Pujol, Francesc Bulut, Sanja Hessman, Charlotte Karabelas, Kostas Nieto, Carles Fernandez-Campos, Francisco Pharmaceutics Article The European Medical Agency (EMA) has issued a draft guideline on the quality and equivalence of topical products. The equivalence for complex semisolid formulations involves several steps: the same quantitative content, the same microstructure, the same release, and permeation profile. In this paper, several batches of a low strength topical product, which we used as a reference/comparator product, were evaluated according to the recommendations of the EMA draft guideline. The batches were 0.025% capsaicin emulsions from the same manufacturer that were evaluated in terms of droplet size, X-ray diffraction patterns, rheology, release, and permeation profile. The generated data revealed a large batch-to-batch variability, and if the EMA guideline was applied, these batches would not be considered equivalent, although they were produced by the same manufacturer. The result of this work illustrates the difficulties in obtaining equivalence according to the current draft guidelines. It also highlights that the equivalence guidelines should consider the variability of the comparator product, and in our opinion, the guidelines should allow for claiming equivalence by comparing the limits in the variability of the data generated for the comparator product with the limits in the variability of the data generated for the intended equivalence product. MDPI 2021-12-04 /pmc/articles/PMC8705898/ /pubmed/34959364 http://dx.doi.org/10.3390/pharmaceutics13122083 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Navarro-Pujol, Francesc
Bulut, Sanja
Hessman, Charlotte
Karabelas, Kostas
Nieto, Carles
Fernandez-Campos, Francisco
Pilot Equivalence Study Comparing Different Batches of Topical 0.025% Capsaicin Emulsion: Product Microstructure, Release, and Permeation Evaluation
title Pilot Equivalence Study Comparing Different Batches of Topical 0.025% Capsaicin Emulsion: Product Microstructure, Release, and Permeation Evaluation
title_full Pilot Equivalence Study Comparing Different Batches of Topical 0.025% Capsaicin Emulsion: Product Microstructure, Release, and Permeation Evaluation
title_fullStr Pilot Equivalence Study Comparing Different Batches of Topical 0.025% Capsaicin Emulsion: Product Microstructure, Release, and Permeation Evaluation
title_full_unstemmed Pilot Equivalence Study Comparing Different Batches of Topical 0.025% Capsaicin Emulsion: Product Microstructure, Release, and Permeation Evaluation
title_short Pilot Equivalence Study Comparing Different Batches of Topical 0.025% Capsaicin Emulsion: Product Microstructure, Release, and Permeation Evaluation
title_sort pilot equivalence study comparing different batches of topical 0.025% capsaicin emulsion: product microstructure, release, and permeation evaluation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705898/
https://www.ncbi.nlm.nih.gov/pubmed/34959364
http://dx.doi.org/10.3390/pharmaceutics13122083
work_keys_str_mv AT navarropujolfrancesc pilotequivalencestudycomparingdifferentbatchesoftopical0025capsaicinemulsionproductmicrostructurereleaseandpermeationevaluation
AT bulutsanja pilotequivalencestudycomparingdifferentbatchesoftopical0025capsaicinemulsionproductmicrostructurereleaseandpermeationevaluation
AT hessmancharlotte pilotequivalencestudycomparingdifferentbatchesoftopical0025capsaicinemulsionproductmicrostructurereleaseandpermeationevaluation
AT karabelaskostas pilotequivalencestudycomparingdifferentbatchesoftopical0025capsaicinemulsionproductmicrostructurereleaseandpermeationevaluation
AT nietocarles pilotequivalencestudycomparingdifferentbatchesoftopical0025capsaicinemulsionproductmicrostructurereleaseandpermeationevaluation
AT fernandezcamposfrancisco pilotequivalencestudycomparingdifferentbatchesoftopical0025capsaicinemulsionproductmicrostructurereleaseandpermeationevaluation